Bank of America Securities analyst Jason Gerberry has maintained their bullish stance on JAZZ stock, giving a Buy rating yesterday.
Jason Gerberry has given his Buy rating due to a combination of factors that suggest the recent sell-off of Jazz Pharmaceuticals’ stock may be overdone. Despite concerns over potential tariffs on drugs imported from Ireland, which could impact Jazz’s Xywav product, the company has several strategies to mitigate these effects. Jazz has indicated that it can manage short-term tariff impacts by utilizing its existing US-based inventory and potentially shifting production to a US-based third-party manufacturer, which would avoid customs tariffs.
Furthermore, Jazz Pharmaceuticals is currently trading at attractive valuation multiples, and the market may have overreacted to the tariff news. The company’s ability to increase US production without needing new FDA or DEA approvals, combined with potential upside from its Phase 3 zani program, supports a positive outlook. These factors, along with the possibility of renegotiating production terms with its contract manufacturing organization, underpin Gerberry’s confidence in maintaining a Buy rating for Jazz Pharmaceuticals.
According to TipRanks, Gerberry is an analyst with an average return of -1.0% and a 43.79% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Exelixis, Axsome Therapeutics, and Jazz Pharmaceuticals.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $210.00 price target.